Trial Profile

A Phase 1, Open-label, Multi-center, Single-dose, Parallel Group Study to Evaluate the Pharmacokinetics of Siremadlin (HDM201) in Participants With Mild, Moderate and Severe Hepatic Impairment Compared to Matched Healthy Control Participants

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 26 Oct 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Siremadlin (Primary)
Indications Acute myeloid leukaemia; Colorectal cancer; Haematological malignancies; Liposarcoma; Myelodysplastic syndromes; Myelofibrosis; Soft tissue sarcoma; Solid tumours; Uveal melanoma
Focus Pharmacokinetics
Sponsors Novartis Pharmaceuticals

19 Oct 2023 Status changed from recruiting to completed.
19 Dec 2022 Planned End Date changed from 19 Sep 2023 to 2 Oct 2023.
19 Dec 2022 Planned primary completion date changed from 19 Sep 2023 to 2 Oct 2023.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com